Punam Malik

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi request reprint Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator
    Punam Malik
    Saban Research Institute, Division of Hematology Oncology, Childrens Hospital Los Angeles, Department of Pediatrics, Los Angeles, California 90027, USA
    Ann N Y Acad Sci 1054:238-49. 2005
  2. ncbi request reprint Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector
    Geetha Puthenveetil
    Saban Research Institute, Division of Hematology Oncology, Childrens Hospital Los Angeles, Mail Stop 54, 4650 Sunset Blvd, Los Angeles, CA 90027, USA
    Blood 104:3445-53. 2004
  3. ncbi request reprint Self-inactivating lentiviral vectors resist proviral methylation but do not confer position-independent expression in hematopoietic stem cells
    Azim Mohamedali
    Division of Hematology Oncology, Children s Hospital Los Angeles and University of Southern California Keck School of Medicine, 90027, USA
    Mol Ther 10:249-59. 2004
  4. ncbi request reprint Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element
    Paritha I Arumugam
    Division of Hematology Oncology, The Saban Research Institute, Children s Hospital Los Angeles, Los Angeles, California, USA
    Mol Ther 15:1863-71. 2007
  5. pmc Involvement of miR-30c and miR-301a in immediate induction of plasminogen activator inhibitor-1 by placental growth factor in human pulmonary endothelial cells
    Nitin Patel
    Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Biochem J 434:473-82. 2011
  6. pmc Placenta growth factor (PlGF), a novel inducer of plasminogen activator inhibitor-1 (PAI-1) in sickle cell disease (SCD)
    Nitin Patel
    Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, USA
    J Biol Chem 285:16713-22. 2010
  7. ncbi request reprint Gene therapy for hemoglobinopathies: are we there yet?
    Geetha Puthenveetil
    Children s Hospital Los Angeles, Mail Stop 54, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
    Curr Hematol Rep 3:298-305. 2004
  8. pmc Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease
    Nitin Patel
    Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Blood 113:1129-38. 2009
  9. ncbi request reprint Pathophysiology and therapy for haemoglobinopathies. Part I: sickle cell disease
    Catherine Madigan
    Hematology Oncology, Childrens Hospital Los Angeles, Mail Stop 54, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
    Expert Rev Mol Med 8:1-23. 2006
  10. pmc Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1 alpha
    Nitin Patel
    Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Blood 112:856-65. 2008

Research Grants

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator
    Punam Malik
    Saban Research Institute, Division of Hematology Oncology, Childrens Hospital Los Angeles, Department of Pediatrics, Los Angeles, California 90027, USA
    Ann N Y Acad Sci 1054:238-49. 2005
    ..Results show genetic correction of primitive human progenitor cells and normalization of the human thalassemia major phenotype...
  2. ncbi request reprint Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector
    Geetha Puthenveetil
    Saban Research Institute, Division of Hematology Oncology, Childrens Hospital Los Angeles, Mail Stop 54, 4650 Sunset Blvd, Los Angeles, CA 90027, USA
    Blood 104:3445-53. 2004
    ..Our results show genetic modification of primitive progenitor cells with correction of the human thalassemia major phenotype...
  3. ncbi request reprint Self-inactivating lentiviral vectors resist proviral methylation but do not confer position-independent expression in hematopoietic stem cells
    Azim Mohamedali
    Division of Hematology Oncology, Children s Hospital Los Angeles and University of Southern California Keck School of Medicine, 90027, USA
    Mol Ther 10:249-59. 2004
    ..Taken together, these data show that erythroid-specific SIN-LV express long term and resist methylation-associated proviral silencing, but may require additional elements to confer position-independent expression...
  4. ncbi request reprint Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element
    Paritha I Arumugam
    Division of Hematology Oncology, The Saban Research Institute, Children s Hospital Los Angeles, Los Angeles, California, USA
    Mol Ther 15:1863-71. 2007
    ..These studies have important implications for vector design for clinical trials for gene therapy for hemoglobinopathies...
  5. pmc Involvement of miR-30c and miR-301a in immediate induction of plasminogen activator inhibitor-1 by placental growth factor in human pulmonary endothelial cells
    Nitin Patel
    Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Biochem J 434:473-82. 2011
    ..Finally, plasma levels of miR-30c and miR-301a were significantly down-regulated in patients with SCA compared with normal controls. These results provide a post-transcriptional regulatory mechanism of PlGF-induced PAI-1 elevation...
  6. pmc Placenta growth factor (PlGF), a novel inducer of plasminogen activator inhibitor-1 (PAI-1) in sickle cell disease (SCD)
    Nitin Patel
    Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, USA
    J Biol Chem 285:16713-22. 2010
    ..In conclusion, we identify a novel mechanism of PAI-1 elevation in SCD...
  7. ncbi request reprint Gene therapy for hemoglobinopathies: are we there yet?
    Geetha Puthenveetil
    Children s Hospital Los Angeles, Mail Stop 54, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
    Curr Hematol Rep 3:298-305. 2004
    ....
  8. pmc Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease
    Nitin Patel
    Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Blood 113:1129-38. 2009
    ..Herein, we identify a mechanism of increased LT in SCD and show HIF-1alpha as a hypoxia-independent target of PlGF. These studies provide new avenues to ameliorate these complications...
  9. ncbi request reprint Pathophysiology and therapy for haemoglobinopathies. Part I: sickle cell disease
    Catherine Madigan
    Hematology Oncology, Childrens Hospital Los Angeles, Mail Stop 54, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
    Expert Rev Mol Med 8:1-23. 2006
    ..It then focuses on the promising targeted therapies currently in use or under investigation. An accompanying article on haemoglobinopathies (Part II) focuses on thalassaemias...
  10. pmc Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1 alpha
    Nitin Patel
    Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Blood 112:856-65. 2008
    ..PlGF levels are intrinsically elevated from the increased red cell turnover in SCD and in other chronic anemia (eg, thalassemia) and may contribute to inflammation and PHT seen in these diseases...
  11. ncbi request reprint Report on the workshop "New Technologies in Stem Cell Research," Society for Pediatric Research, San Francisco, California, April 29, 2006
    Jerry C Cheng
    Division of Hematology Oncology, Department of Pediatrics, Gwynne Hazen Cherry Memorial Laboratories and Mattel Children s Hospital, Jonsson Comprehensive Cancer Center, Los Angeles, California, USA
    Stem Cells 25:1070-88. 2007
  12. ncbi request reprint Human CD34(+) and CD34(+)CD38(-) hematopoietic progenitors in sickle cell disease differ phenotypically and functionally from normal and suggest distinct subpopulations that generate F cells
    Lori Luck
    Division of Hematology Oncology, Childrens Hospital Los Angeles, Los Angeles, CA 90027, USA
    Exp Hematol 32:483-93. 2004
    ..Sickle cell disease (SCD) is remarkable for stress erythropoiesis. We investigated the progenitor populations contributing to erythroid stress...
  13. ncbi request reprint Pathophysiology and therapy for haemoglobinopathies. Part II: thalassaemias
    Fabrizia Urbinati
    Hematology Oncology, Childrens Hospital Los Angeles, Mail Stop 54, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
    Expert Rev Mol Med 8:1-26. 2006
    ..An accompanying article on haemoglobinopathies (Part I) focuses on sickle cell disease...
  14. ncbi request reprint Placenta growth factor activates monocytes and correlates with sickle cell disease severity
    Natalya Perelman
    Division of Hematology Oncology, Childrens Hospital Los Angeles, CA 90027, USA
    Blood 102:1506-14. 2003
    ..The baseline inflammation seen in SCD has always been attributed to sequelae secondary to the sickling phenomenon. We show that PlGF contributes to the inflammation observed in SCD and increases the incidence of vaso-occlusive events...

Research Grants6

  1. Role of Placenta Growth factor in Sickle ACS
    MALIK PUNAM; Fiscal Year: 2007
    ..VEGFR-antagonists are in clinical trials and leukotriene blockers are FDA approved and in clinical use for asthma and could be candidates for an ACS prevention trial. ..
  2. Lentiviral vectors for gene therapy for beta-thalassemia
    Punam Malik; Fiscal Year: 2006
    ..Together, these aims comprise a focussed research program to produce therapeutic and sustained levels of B-globin in human thalassemia RBCs, and form the basis for future preclinical studies. ..